艾滋病相关淋巴瘤的发病机制、诊断与治疗进展

Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma.

作者信息

Little Richard F., Wilson Wyndham H.

机构信息

*HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 10S255, 10 Center Drive MSC 1868, Bethesda, MD 20892-1868, USA.

出版信息

Curr Infect Dis Rep. 2003 Apr;5(2):176-184. doi: 10.1007/s11908-003-0055-1.

DOI:10.1007/s11908-003-0055-1

PMID:12642005

Abstract

AIDS-related non-Hodgkin's lymphoma (ARL) is an opportunistic malignancy that foreshortens life more than any other commonly occurring HIV-associated cancer. Treatment strategies include low-dose chemotherapy, chemotherapy given with antiretroviral therapy, and infusional chemotherapy regimens. Rituximab, an anti-CD20 monoclonal antibody, has been found to be useful in non-HIV-associated lymphomas and is of interest in ARL as well. Since the advent of highly active antiretroviral therapy, the ARL incidence and survival has changed. This paper reviews the epidemiologic, biologic, and clinical features of ARL with the aim of presenting a cohesive overview of these elements.

摘要

艾滋病相关非霍奇金淋巴瘤（ARL）是一种机会性恶性肿瘤，比任何其他常见的与HIV相关的癌症更能缩短生命。治疗策略包括低剂量化疗、与抗逆转录病毒疗法联合使用的化疗以及输注化疗方案。利妥昔单抗是一种抗CD20单克隆抗体，已被发现可用于非HIV相关淋巴瘤，在ARL中也受到关注。自从高效抗逆转录病毒疗法问世以来，ARL的发病率和生存率已经发生了变化。本文综述了ARL的流行病学、生物学和临床特征，旨在对这些要素进行全面的概述。